Columbia University Herbert Irving Comprehensive Cancer Center | Strategic Alliance Partners

At the Herbert Irving Comprehensive Cancer Center at Columbia University and NewYork-Presbyterian Hospital, we believe that our discoveries here will end cancer everywhere.
Working together, we empower innovation and discovery in prevention, research and clinical care to reduce the burden of cancer for our patients, our community, and the world.

Latest from Columbia University Herbert Irving Comprehensive Cancer Center

Novel Tomography System May Help Guide Therapy in Early Breast Cancer

January 08, 2014

Article

Diffuse optical tomography (DOT) is a novel, fast, safe, and low-cost technique that uses near-infrared light to provide three-dimensional data on tissue vascularity without the use of radiation.

Molecular Signature Distinguishes Indolent From Aggressive Prostate Cancer

November 08, 2013

Article

Prostate cancer is one of the most common forms of cancer in older men, with more than 200,000 new diagnoses per year.

Dr. Hershman on Adherence to Longer Hormonal Therapy

August 01, 2013

Video

Dawn L. Hershman, MD, MS, Associate Professor of Medicine and Epidemiology, Leader, Breast Cancer Program, Herbert Irving Comprehensive Cancer Center, Columbia University, discusses the need for adherence with longer hormonal therapy.

Dr. Hershman on the Use of Compendia-Approved Drugs

June 17, 2013

Video

Dawn L. Hershman, MD, MS, discusses improving care and the use of compendia-approved oncology drugs.

Herbert Irving Comprehensive Cancer Center Joins OncLive's Strategic Alliance Partnership

May 07, 2013

Article

OncLive is pleased to announce that the Herbert Irving Comprehensive Cancer Center has joined its Strategic Alliance Partnership program.

NewYork-Presbyterian/Columbia & Cornell Cancer Program: Collaborating for Advances in Research and Patient Care

November 13, 2012

Article

In September 2012 the new joint Cancer Center at Weill Cornell Medical College and NewYork-Presbyterian Hospital was established, bringing together basic, translational, and clinical researchers to operate within a vast, collaborative infrastructure.

Dr. Petrylak Discusses the Future of Abiraterone Acetate

April 27, 2012

Video

Dr. Daniel Petrylak, from the Herbert Irving Comprehensive Cancer Center, Discusses the Future of Abiraterone Acetate

Dr. Petrylak on Chemotherapy in Prostate Cancer

April 11, 2012

Video

Dr. Daniel Petrylak, from Columbia University Medical Center, Discusses Chemotherapy in Prostate Cancer

Lenalidomide Plus Docetaxel: Phase III Results Fall Short

February 03, 2012

Article

The combination of lenalidomide and docetaxel for treatment of CRPC failed to produce results in the large phase III MAINSAIL trial.

Dr. Petrylak on Sequencing Prostate Cancer Therapies

December 01, 2011

Video

Dr. Daniel Petrylak from Herbert Irving Comprehensive Cancer Center Discusses Sequencing Prostate Cancer Therapies

Changing Fate of Bone-Related Therapies for Prostate Cancer

October 18, 2011

Article

Two trials are underway that not only address bone-related issues but might improve survival rates for patients.

Dr. Petrylak Explains Prostate Cancer Clinical Trial Difficulties

March 28, 2011

Video

Daniel P. Petrylak, MD, from Columbia University Medical Center Explains the Difficulties Facing During Prostate Cancer Clinical Trials